COMMONWEALTH EQUITY SERVICES, LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 294 filers reported holding BIO-TECHNE CORP in Q4 2017. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
COMMONWEALTH EQUITY SERVICES, LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$1,070
-15.0%
15,716
+1.9%
0.00%
-33.3%
Q2 2023$1,259
+4.7%
15,418
-5.0%
0.00%0.0%
Q1 2023$1,203
-39.9%
16,228
-32.9%
0.00%
-40.0%
Q4 2022$2,003
-99.9%
24,174
+289.5%
0.01%0.0%
Q3 2022$1,762,000
-14.4%
6,206
+4.5%
0.01%0.0%
Q2 2022$2,058,000
-12.3%
5,937
+9.6%
0.01%0.0%
Q1 2022$2,346,000
-16.9%
5,418
-0.7%
0.01%
-16.7%
Q4 2021$2,823,000
-34.3%
5,458
-38.4%
0.01%
-45.5%
Q3 2021$4,296,000
+76.4%
8,866
+63.9%
0.01%
+83.3%
Q2 2021$2,435,000
+8.7%
5,408
-7.8%
0.01%0.0%
Q1 2021$2,241,000
+28.1%
5,868
+6.4%
0.01%
+20.0%
Q4 2020$1,750,000
+3.1%
5,513
-19.5%
0.01%
-16.7%
Q3 2020$1,697,000
+49.1%
6,850
+58.9%
0.01%
+50.0%
Q2 2020$1,138,000
+32.6%
4,312
-4.7%
0.00%0.0%
Q1 2020$858,000
-14.2%
4,527
-0.6%
0.00%0.0%
Q4 2019$1,000,000
+11.1%
4,556
-1.0%
0.00%0.0%
Q3 2019$900,000
-0.8%
4,600
+5.6%
0.00%0.0%
Q2 2019$907,000
+19.0%
4,354
+13.4%
0.00%0.0%
Q1 2019$762,000
+42.7%
3,841
+4.1%
0.00%
+33.3%
Q4 2018$534,000
-27.9%
3,690
+1.6%
0.00%
-25.0%
Q3 2018$741,000
-52.1%
3,632
-65.3%
0.00%
-50.0%
Q2 2018$1,547,000
+156.1%
10,456
+161.4%
0.01%
+166.7%
Q1 2018$604,000
+16.8%
4,000
+0.2%
0.00%0.0%
Q4 2017$517,0003,9930.00%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2017
NameSharesValueWeighting ↓
Brown Capital Management 2,119,107$256,179,0003.12%
STONE RUN CAPITAL, LLC 42,925$5,189,0002.67%
440 INVESTMENT GROUP, LLC 27,820$3,363,0002.56%
Summit Creek Advisors LLC 106,517$12,877,0002.54%
MAIRS & POWER INC 1,444,480$174,623,0002.10%
QUANTUM CAPITAL MANAGEMENT 57,094$6,902,0001.63%
Select Equity Group, L.P. 1,709,914$206,711,503,0001.57%
FRIESS ASSOCIATES LLC 144,610$17,482,0001.53%
Tygh Capital Management, Inc. 61,813$7,473,0001.49%
First Light Asset Management, LLC 38,654$4,673,0001.48%
View complete list of BIO-TECHNE CORP shareholders